Journal Club- Guideline led COPD Management: Vilanterol or formoterol? - Video
|
Overview
This review has been published in the Annals of the National Academy of Medical Sciences published by Scientific Scholar.
This comprehensive review evaluates the comparative efficacy, safety, and clinical advantages of vilanterol versus formoterol in the management of obstructive airway diseases, with a specific focus on the latest Global Initiative for Asthma (GINA) 2024 and Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 guideline recommendations.
Vilanterol, a novel long-acting β2-agonist (LABA), 24-hour duration of action, once-daily dosing when compared to formoterol’s twice-daily requirement.
Clinical trials in both asthma and chronic obstructive pulmonary disease (COPD) have shown vilanterol-containing combinations to be at least as effective as formoterol-based treatments in improving lung function, symptom control, and quality of life.
However, the GINA 2024 guidelines emphasize formoterol’s role in as-needed and maintenance and reliever therapy (MART) approaches for asthma management.
In COPD, Vilanterol aligns well with GOLD 2024 recommendations, particularly in fixed-dose combinations. Safety analyses indicate a favorable profile for vilanterol, even in high-risk populations. The once-daily dosing of vilanterol offers potential improvements in patient adherence and satisfaction, especially relevant in COPD management.
While direct cost comparisons are limited, improved clinical outcomes suggest potential cost-effectiveness benefits.
This review concludes that while vilanterol presents several advantages, particularly in COPD management and once-daily regimens, the choice between vilanterol and formoterol should be individualized based on patient characteristics, disease features, and current guideline recommendations.
Speakers
Dr. Garima Soni
BDS, MDS(orthodontics)
Dr. Garima Soni holds a BDS (Bachelor of Dental Surgery) from Government Dental College, Raipur, Chhattisgarh, and an MDS (Master of Dental Surgery) specializing in Orthodontics and Dentofacial Orthopedics from Maitri College of Dentistry and Research Centre. At medical dialogues she focuses on dental news and dental and medical fact checks against medical/dental mis/disinformation
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751